Acumen Research and Consulting Recombinant Plasma Protein Therapeutics Market | Page 3

Hemophilia Foundation Australia (HFA). Therefore, an increase in recombinant therapies is projected to drive the market during the predicted period for hemophilia treatment. Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs Key Players and Strategies The Recombinant Plasma Protein Therapeutics market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are Bayer AG, Novo Nordisk A / S, Aptevo Therapeutics, Octapharma, Pharma Group NV, Bioverativ Therapeutics, Inc. (Sanofi),Pfizer Inc., and CSL Limited, Shire (Takeda Pharmaceutical Company Limited) among others. These companies are able to expand their global market presence through new product launch, purchasing, geographical expansion, collaborations and distribution agreements. Takeda Pharmaceutical Company Limited, a pharmaceutical company based in Japan, was acquired by Shire in January 2019. This acquisition aims to strengthen the geographic presence of Takeda Pharmaceutical Company Limited. Bioverativ Therapeutics Inc., which operates as part of Sanofi Genzyme, has been acquired by Sanofi, the leading pharmaceutical company, in January 2018. Many other players on the market have also taken steps to expand their business in emerging markets. Leading players in the Asia Pacific, such as China, Japan and Australia, also concentrate on increasing their customer base. Market participants are also supporting several campaigns to increase awareness about hematological disorder and the availability and advantages offered by such products of treatments, such as recombinant plasma proteins. Would like to place an order or any question, please feel free to contact at [email protected] | [phone]